Pharmacology, Biochemistry, and Behavior
July 2018
Yun Wang, Liming Xie, Ce Gao et al.
Depression is a common, debilitating mood disorder, but currently available antidepressants have several major drawbacks. Both ketamine and scopolamine attract more and more attention due to their rapid and sustained antidepressant activities. However, the molecular and cellular mechanism that underlies the therapeutic action of ketamine and scopolamine still remain to be elucidated....
FOCUS: The Journal of Lifelong Learning in Psychiatry
July 1, 2018
Gerard Sanacora, Rachel B. Katz
16 citations
A growing series of clinical trials and case series now suggest that ketamine-originally used as an anesthetic agent-potentially offers an exciting new treatment option for severe depression. Increasing numbers of studies show that ketamine can provide prompt relief for many depressed patients, including those with severe treatment-refractory depression. Although the effects of a single...
Journal of Psychiatric Practice
July 1, 2018
Lai Fong Chan, Choon Leng Eu, Shean Yih Soh et al.
18 citations
Ketamine has shown effectiveness as a rapid-acting antidepressant with antisuicidal effects in terms of reduction of suicidal ideation in the short term. However, the evidence for long-term maintenance ketamine therapy for treatment-resistant depression (TRD) and suicidal behavior is limited. This case series (N=13) highlights the role of adjunctive serial maintenance ketamine infusions in...
Pharmacological Reviews
June 26, 2018
Panos Zanos, Ruin Moaddel, Patrick J. Morris et al.
1,272 citations
Ketamine, a racemic mixture consisting of (S)- and (R)-ketamine, has been in clinical use since 1970. Although best characterized for its dissociative anesthetic properties, ketamine also exerts analgesic, anti-inflammatory, and antidepressant actions. We provide a comprehensive review of these therapeutic uses, emphasizing drug dose, route of administration, and the time course of these...
Current Pharmaceutical Biotechnology
June 21, 2018
Moritz Haaf, Gregor Leicht, Stjepan Curic et al.
53 citations
BACKGROUND: The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. NMDAR hypofunction can explain many schizophrenia symptoms directly due to...
Psychiatry and Clinical Neurosciences
June 19, 2018
R. Pérez-Esparza, T. Corona, R. Ruiz-García et al.
Growing evidence of the rapid antidepressant effects of ketamine represents a promising advance in treatment-resistant depression (TRD) therapeutics. Most studies provide information after treatment washout, reporting response up to 7 days and remission up to 3-5 days after a single dose.
Psychopharmacology
June 14, 2018
Cheol Lee, Juhwan Lee, Gilho Lee et al.
It has been known that anesthetic adjuvants such as dexamethasone or ketamine might change mood. This study aimed to investigate the effects of a single dose of each drug individually along with their combined usage on postoperative mood changes in patients undergoing gynecologic surgery. Two hundred ninety-seven patients randomly allocated were divided into three groups. Group K (n = 99)...
Neuroreport
June 13, 2018
Bin Lian, Jinjun Xia, Xun Yang et al.
In the present study, we used a gas chromatography-mass spectrometry-based metabolomics method to evaluate the effects of ketamine on mice hippocampi. Multivariate statistical analysis and ingenuity pathway analysis were then used to identify and explore the potential mechanisms and biofunction of ketamine. Compared with the control (CON) group, 14 differential metabolites that involved amino...
IBRO Reports
June 13, 2018
Glauce Socorro de Barros Viana, Cecilia Coelho Xavier, Eduardo Mulato Do Vale et al.
10 citations
Ketamine (KET), a NMDA receptor antagonist, has been studied for its rapid and efficacious antidepressant effect, even for the treatment-resistant depression. Although depression is a major cause of disability worldwide, the treatment can be feasible, affordable and cost-effective, decreasing the population health burden. We evaluated the antidepressive-like effects of KET and its actions on...
The International Journal of Neuropsychopharmacology
June 6, 2018
Lijia Chang, Hidetoh Toki, Youge Qu et al.
26 citations
Background: Although previous reports suggest sex-specific differences in the antidepressant actions of (R,S)-ketamine, these differences in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, are unknown. Methods: Saline or (R)-ketamine was administered 23 hours post lipopolysaccharide administration to adult male or female mice. Subsequently, antidepressant...